Dolan ME - Search Results

1

Drug focus: Pharmacogenetic studies related to cyclophosphamide-based therapy.

Pinto N, Ludeman SM, Dolan ME. Pinto N, et al. Among authors: dolan me. Pharmacogenomics. 2009 Dec;10(12):1897-903. doi: 10.2217/pgs.09.134. Pharmacogenomics. 2009. PMID: 19958089 Free PMC article. Review.

2

Role of MGMT in protecting against cyclophosphamide-induced toxicity in cells and animals.

Hansen RJ, Ludeman SM, Paikoff SJ, Pegg AE, Dolan ME. Hansen RJ, et al. Among authors: dolan me. DNA Repair (Amst). 2007 Aug 1;6(8):1145-54. doi: 10.1016/j.dnarep.2007.03.010. Epub 2007 May 7. DNA Repair (Amst). 2007. PMID: 17485251 Free PMC article.

3

Clinically relevant genetic variations in drug metabolizing enzymes.

Pinto N, Dolan ME. Pinto N, et al. Among authors: dolan me. Curr Drug Metab. 2011 Jun;12(5):487-97. doi: 10.2174/138920011795495321. Curr Drug Metab. 2011. PMID: 21453273 Free PMC article. Review.

4

Selective enhancement of ifosfamide-induced toxicity in Chinese hamster ovary cells.

Smith SM, Ludeman SM, Wilson LR, Springer JB, Gandhi MC, Dolan ME. Smith SM, et al. Among authors: dolan me. Cancer Chemother Pharmacol. 2003 Oct;52(4):291-302. doi: 10.1007/s00280-003-0672-2. Epub 2003 Jul 4. Cancer Chemother Pharmacol. 2003. PMID: 12845477

5

Role of O6-alkylguanine-DNA alkyltransferase in protecting against cyclophosphamide-induced toxicity and mutagenicity.

Cai Y, Wu MH, Ludeman SM, Grdina DJ, Dolan ME. Cai Y, et al. Among authors: dolan me. Cancer Res. 1999 Jul 1;59(13):3059-63. Cancer Res. 1999. PMID: 10397244

6

Effect of O6-benzylguanine on alkylating agent-induced toxicity and mutagenicity. In Chinese hamster ovary cells expressing wild-type and mutant O6-alkylguanine-DNA alkyltransferases.

Cai Y, Wu MH, Xu-Welliver M, Pegg AE, Ludeman SM, Dolan ME. Cai Y, et al. Among authors: dolan me. Cancer Res. 2000 Oct 1;60(19):5464-9. Cancer Res. 2000. PMID: 11034089

7

Integrating cell-based and clinical genome-wide studies to identify genetic variants contributing to treatment failure in neuroblastoma patients.

Pinto N, Gamazon ER, Antao N, Myers J, Stark AL, Konkashbaev A, Im HK, Diskin SJ, London WB, Ludeman SM, Maris JM, Cox NJ, Cohn SL, Dolan ME. Pinto N, et al. Among authors: dolan me. Clin Pharmacol Ther. 2014 Jun;95(6):644-52. doi: 10.1038/clpt.2014.37. Epub 2014 Feb 18. Clin Pharmacol Ther. 2014. PMID: 24549002 Free PMC article.

8

Using germline genomics to individualize pediatric cancer treatments.

Pinto N, Cohn SL, Dolan ME. Pinto N, et al. Among authors: dolan me. Clin Cancer Res. 2012 May 15;18(10):2791-800. doi: 10.1158/1078-0432.CCR-11-1938. Clin Cancer Res. 2012. PMID: 22589487 Free PMC article. Review.

9

Trans-population analysis of genetic mechanisms of ethnic disparities in neuroblastoma survival.

Gamazon ER, Pinto N, Konkashbaev A, Im HK, Diskin SJ, London WB, Maris JM, Dolan ME, Cox NJ, Cohn SL. Gamazon ER, et al. Among authors: dolan me. J Natl Cancer Inst. 2013 Feb 20;105(4):302-9. doi: 10.1093/jnci/djs503. Epub 2012 Dec 14. J Natl Cancer Inst. 2013. PMID: 23243203 Free PMC article.

10

Approaches to the discovery of pharmacogenomic markers in oncology: 2000-2010-2020.

Huang RS, Dolan ME. Huang RS, et al. Among authors: dolan me. Pharmacogenomics. 2010 Apr;11(4):471-4. doi: 10.2217/pgs.10.11. Pharmacogenomics. 2010. PMID: 20350124 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

323 results

Search Page